Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Apr 28, 2016
Last Price Change Open Day High 52-Week High
16.84
0.39  down   (2.263%) 17.34 17.62 120.96
Volume Previous Close Day Low 52-Week Low
279,602 17.23 16.76 12.61

View all »   RSSRecent Releases

Mar 8, 2016
Esperion Therapeutics to Present at the Barclays Global Healthcare Conference

Feb 25, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results